A tough retirement nest egg, the whistle-blowing way
By
James M. Berklan
Nov 07, 2013
Two big reactions hit me when news of Johnson & Johnson’s $2.2 billion Risperdal settlement with the government landed this week. First, J&J probably made a lot more than it’s paying out and,...